rigel pharmaceuticals stock history
AP _ Rigel Pharmaceuticals Inc. It markets its lead candidate FOTIVDA an oral once-daily vascular endothelial growth factor receptor tyrosine kinase inhibitor which is used for the treatment of renal cell carcinoma RCC.
28 Stocks That Could Double In Two Years No Matter What The Market Does Stock Picks Marketing Health Care
View the best growth stocks for 2022 here.
. RIGL today reported financial results for the second quarter ended June 30 2022 including sales of TAVALISSE fostamatinib disodium hexahydrate tablets. And tivozanib for the treatment. Rigel Pharmaceuticals stock was trading at 265 at the beginning of the year.
SOUTH SAN FRANCISCO Calif. 2019 Agenda Press releases Corporate governance Corporate Stewardship Reports Presentations Stock information. On a per-share basis the South San Francisco California.
RIGL Rigel Pharmaceuticals Inc Current Report Filing 8-k Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 230405 of this chapter or Rule 12b-2 of the Securities Exchange Act of 1934 24012b-2 of this chapter. RIGL to a Street High 1500 from 700 while. AVEO Pharmaceuticals Inc a biopharmaceutical company focuses on developing and commercializing medicines for cancer patients.
Updated - August 18 2022 916 AM EDT HC. Our unique and remarkable history combines scientific expertise with a desire to serve patients and society. RIGL on Tuesday reported a loss of 135 million in its second quarter.
Wainwright analyst Joseph Pantginis raised the price target on Rigel Pharmaceuticals NASDAQ. Rigel Pharmaceuticals Inc. January 23 2019 Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals.
Since then RIGL shares have decreased by 396 and is now trading at 160.
28 Stocks That Could Double In Two Years No Matter What The Market Does Stock Picks Marketing Health Care
28 Stocks That Could Double In Two Years No Matter What The Market Does Stock Picks Marketing Health Care
Pin On Go Boldly Brilliant Biotechs